Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule

• U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
• Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™ (Zeta-BC-003)
• New patent further enhances the Company’s Global IP strategy

April 23, 2019 – (Syracuse, New York) - Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, announced today that the U.S. Patent and Trademark Office (“USPTO”) issued U.S. Patent No. 102656437 to the Company. This patent, entitled Neurogenic Regulation of Bone Growth and Bone Degradation, covers the use of methods for promoting controlled bone creation and destruction as a means to repair large bone segmental defects. This patent follows the previously issued U.S. Patent No. 10208306 and South African PCT. 2017/00029 covering the use of a method for stimulating bone growth using a small molecule.

“This latest patent issuance is a significant piece of our Global IP Strategy. This provides the opportunity to further develop our therapies to aid patients afflicted by metastatic lesions,” said Joe C. Loy, CEO of Zetagen Therapeutics, Inc.

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions and osteologic interventions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.